A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis B
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2018
At a glance
- Drugs GS 9688 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 09 Jul 2018 Planned number of patients changed from 40 to 60.
- 04 May 2017 Status changed from not yet recruiting to recruiting.
- 17 Feb 2017 New trial record